Agile Therapeutics Acknowledges New Government Guidance Reinforcing Requirement to Cover Contraceptives that a Woman and Her Heathcare Provider Determine are Medically Appropriate at No Cost
12 janv. 2022 17h29 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- On January 10, 2022, the tri-agencies, Department of Labor (DOL), Health and Human Services (HHS) and Treasury issued new guidance that supports...
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
09 janv. 2022 14h00 HE
|
Emergent BioSolutions
Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA...
Agile Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h03 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will...
Emergent BioSolutions to Participate in Investor Conferences
03 janv. 2022 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...